ATT2_-_ICE_BAA_SPP_Template.xlsx
XLSX spreadsheet 16 KB Posted
- Attached to
- Ice Control for cold Environments (ICE) Federal contract opportunity
- Solicitation number
- HR001122S0047
View the file
Other files for this federal contract opportunity
| File | Type | Posted |
|---|---|---|
| HR001122S0047-Amendment-01.pdf | ||
| ATT3_-_ICE_BAA_SOW_Template.docx | DOCX document | |
| ATT1_-_ICE_BAA_Exec_Sum_Slide_Template.pptx | PPTX presentation | |
| HR001122S0047.pdf |
On GovTribe
Work with this file on GovTribe
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
BSURE
Guidance for completing the ICE Specific Program Plan (SPP):
--Provide key proposal details already described in the full proposal. (Replace existing text below with answers) --All proposers complete Program Detail section --Provide concise answers (no more than 1-3 sentence answers) to each and every Program Detail requested.
--Submit in excel format
| Title | ||
| Lead PI | ||
| Institution(s) | ||
| Item | Topic | Program Detail |
| Phase I - Track I Quantitative Testbed Infrastructure | ||
| 1 | Molecular Diversity | Performers are required to demonstrate that their assay is functional, reproducible, and equivalent across 1) proteins/peptides; 2) polysaccharides; and 3) small molecules |
| 2 | Temperature range | Assays need to be operational and produce equivalent results over a temperature range of +5°C to -30°C |
| 3 | Sample quantities | Assays must be capable of screening candidate molecules over two orders of magnitude in concentration |
| 4 | Robustness | Assays must be capable of performing at least 3 replicates per sample in parallel, achieving results that vary by no more than 5%, and must include appropriate positive and negative controls |
| 5 | Reproducibility | Assay platforms must utilize automated quantitative data collection NOT dependent on subjective interpretations by a human (i.e., microscopy-based approaches dependent on human scoring of activity and performance) |
| 6 | Throughput | Final assays must be capable of screening at least 500 samples (in triplicate) over a continuous 24-hour period |
| 7 | Quality control | The run by run variation (and its sources) in the accuracy and precision of the testbed must be quantified, mitigated, and minimized |
| 8 | Data sharing | Plans for sharing assay approaches/results with other ICE teams (secure infrastructure and servers) |
| Phase I - Track II Candidate Discovery and Library Generation | ||
| 9 | Library approach | Rationale for approach and selection of molecular targets, including estimated formulations for specific DoD application |
| 10 | Library size | Estimation and justification for library size |
| 11 | Justification and risk mitigation for library generation approach | |
| For metagenomics-based approaches and sampling sites, estimated number of sequences, and projected throughput/capacity of sequencing required to generate sufficient data to mine | ||
| High throughput mass spectrometry should detail the estimated number of biological samples or mixtures to be screened and how sufficient chemical diversity can be achieved to enable candidate identification | ||
| In vitro selection, directed evolution, and phage display based techniques must justify selection approaches and describe how significant molecular diversity can be achieved to mitigate risk | ||
| Synthetic chemistry and biochemical approaches must describe the breadth and depth of chemical diversity achievable using the proposed approach(s) | ||
| Bioinformatics/computational methodologies must articulate/justify how the proposed approaches will identify significant candidate diversity to screen for functionality and mitigate risk | ||
| 12 | Data sharing | Combinatorial approaches should detail the advantages over stand alone methods |
| Plans for data sharing with IV&V partner and DARPA |
| Phase II -Accelerated Molecule Engineering for Performance and Formulation | ||
| 13 | Detailed rationale on approach and timelines for iterative molecule design, build, and test to improve activity and enhance performance on molecules transitioned to Phase II. | |
| 14 | A comprehensive justification and rationale for how the selected class of molecules can be functionalized, modified, or incorporated into different formulations/materials such as gels, aqueous solutions, powders, textiles, resins, composites, and coatings, among others that are suitable for use in selected DoD ECW application areas. | |
| 15 | Methods and approaches to determining stability, half-life, activity, toxicity, durability, and efficiency of performance and formulation/incorporation into different material form factors and alternative approaches to mitigate risk. | |
| 16 | Details on approaches to scale-up and a preliminary technoeconomic analysis of costs associated with production of active molecules and incorporation into proposed materials. | |
| 17 | A comprehensive testing plan to assess materials performance relative to selected formulation/ECW application. | |
| 18 | Proposers should include information on alternative approaches and risk mitigation strategies for molecule optimization, materials development, and scale up. |
| Design, Build, Test, and Optimize (DBTO) cycles | ||
| 19 | Anticipated timeline for DBTO cycles and process | |
| 20 | Capacity to produce molecules or materials for testing | |
| 21 | Predictability of scale up potential for molecule or material | |
| 22 | Process documentation to inform IV&V partner | |
| 23 | Plans for data sharing with IV&V and DARPA (secure infrastructure and servers) |
| ECW Application Areas (Select at least one) | ||
| 24 | Frostbite prevention | Injuries to service members resulting from exposure to extreme cold weather is a persistent problem. There are currently minimal technologies for the prevention of frostbite, which results from formation and expansion of ice crystals on and in skin and peripheral tissues. Biological molecules that prevent the formation or growth of ice crystals could potentially be leveraged as an anti-frostbite countermeasure. Incorporation of these molecules into topical formulations such as a gel, hydrogel, cream, dermal polymer, or other appropriate medium may provide a solution. |
| 25 | Critical aqueous solutions | Freezing of critical aqueous solutions such as potable water, IV fluids, and sterile injectable medications is a pressing challenge to sustained operations in ECW. The addition of Biological molecules that could lower the freezing and/or melting points of these critical solutions in a non-toxic manner would be highly desirable. |
| 26 | Green de-icing solutions | Current de-icing fluids are comprised of different mixtures of salts or polyethylene glycol. These fluids are corrosive and toxic to the environment. Non-toxic, environmentally friendly, and low-cost de-icing solutions for runways and aircraft. Biologically sourced and/or inspired molecules could provide a non-toxic, environmentally friendly, and low-cost de-icing alternative for runways and aircraft. |
| 27 | Ground based ice inducers | Ice nucleators for enhanced freezing and ice strengthening at elevated temperatures. Overland vehicles in extreme cold often utilize frozen rivers and “ice bridges” to traverse the rugged terrain of the Arctic. In addition, the Army Corp of Engineers utilizes cleared snow to construct protective barriers/berms to defend against kinetic weapons. Materials incorporating biological ice nucleators could deliver feasibility data and initial proof-of-concept under operationally relevant temperatures and environmental conditions to assess performance, utility, and usability. |
| 28 | Air based ice inducers | Ice nucleators for induction of precipitation or fog. Biological compounds and organisms present in the atmosphere are well documented nucleators of water and ice that can induce cloud formation and precipitation. The ability to induce localized precipitation could be used for fire control and drought mitigation while the formation of “ice fog” would be useful for obscuration applications. Anticipated deliverables include data on performance, dispersal mechanisms, duration, and quantity of material required. |
| 29 | Additional information | Detailed rationale on approach and timelines for iterative molecule design, build, and test to improve activity and enhance performance on molecules transitioned to Phase II. |
| 30 | Additional information | A comprehensive justification and rationale for how the selected class of molecules can be functionalized, modified, or incorporated into different formulations/materials such as gels, aqueous solutions, powders, textiles, resins, composites, and coatings, among others that are suitable for use in selected DoD ECW application areas. |
| 31 | Additional information | Methods and approaches to determining stability, half-life, activity, toxicity, durability, and efficiency of performance and formulation/incorporation into different material form factors and alternative approaches to mitigate risk. |
| 32 | Additional information | Details on approaches to scale-up and a preliminary technoeconomic analysis of costs associated with production of active molecules and incorporation into proposed materials. |
| 33 | Additional information | A comprehensive testing plan to assess materials performance relative to selected formulation/ECW application. |
| 34 | Additional information | Proposers should include information onDetails on alternative approaches and risk mitigation strategies for molecule optimization, materials development, and scale up. |
File details come from the government source that posted it. Updated .